Danaher Q4 Earnings Call Highlights

4 months ago 67

MarketBeat

Wed, January 28, 2026 astatine 9:09 AM CST 7 min read

Danaher logo

Danaher finished 2025 with a "strong finish": income of $24.6 billion, 2% halfway gross growth, adjusted diluted EPS of $7.80 (+4.5%), and free currency travel of $5.3 billion, marking the 34th consecutive twelvemonth its escaped currency travel conversion exceeded 100%.
Investment successful innovation drove astir 25% year-over-year maturation successful caller merchandise revenue, with notable launches successful bioprocessing (Cytiva), beingness sciences (SCIEX ZenoTOF 8600) and diagnostics (Cepheid Xpert GI, Beckman assay expansions); absorption present models astir $1.8 billion of respiratory gross for 2026 successful a emblematic season.
For 2026 Danaher guided 3%–6% halfway gross growth and adjusted EPS of $8.35–$8.50, expects high-single-digit bioprocessing maturation and ~28.5% adjusted operating borderline successful Q1, and said astir $0.30 of EPS upside stems from ~$250 cardinal of 2025 outgo actions portion M&A conditions improve.
Interested successful Danaher Corporation? Here are 5 stocks we similar better.

An AI Play Hiding successful Plain Sight: A Look astatine Johnson Controls

Danaher (NYSE:DHR) closed 2025 with what absorption described arsenic a “strong finish” and better-than-expected show crossed its portfolio, driven by continued spot successful bioprocessing and improving momentum successful diagnostics and beingness sciences. On the company’s fourth-quarter net call, President and CEO Rainer Blair said disciplined execution helped Danaher transcend its expectations for margins, earnings, and currency travel contempt tariff-related outgo pressures and ongoing productivity investments.

For full-year 2025, Danaher reported income of $24.6 cardinal and 2% halfway gross growth. Adjusted operating nett borderline was 28.2%, portion adjusted diluted net per stock were $7.80, up 4.5%. Free currency travel totaled $5.3 billion, translating to a escaped currency flow-to-net income conversion ratio of astir 145%.

→ Kinder Morgan’s Natural Gas/Dividend Growth Cycle Still successful Play

3 Stocks Offering Strong Value and Stability

Blair emphasized the company’s currency procreation way record, noting that 2025 marked the 34th consecutive twelvemonth Danaher’s escaped currency travel conversion exceeded 100%.

Blair said continued concern successful innovation supported an “accelerated cadence” of caller merchandise introductions successful 2025, which contributed to astir 25% year-over-year maturation successful caller merchandise revenue. He highlighted developments crossed the company’s businesses, including:

Bioprocessing (Cytiva): More than 20 caller products crossed biologics workflows, including caller formats of Xcellerex X-platform bioreactors and launches of MabSelect SuRe 70 and MabSelect PrismA X macromolecule A resins.
Life sciences (SCIEX): Introduction of the ZenoTOF 8600 wide spectrometry system, which Blair said delivers up to 30 times accrued sensitivity versus erstwhile platforms.
Diagnostics (Beckman Coulter Diagnostics): Expansion of the DxI 9000 assay menu, including advancement successful neurodegenerative illness and a first-to-market automated high-throughput BD-Tau research-use-only immunoassay, alongside additions successful cardiac and humor microorganism menus.
Molecular diagnostics (Cepheid): FDA clearance for the Xpert GI Panel, a multiplex PCR trial that detects 11 gastrointestinal pathogens from a azygous illustration utilizing the GeneXpert platform.